42P GMP-compliant human monocyte-derived dendritic cells for cancer vaccination generated by using the Quantum ® hollow fiber bioreactor system

ConclusionWe have adapted the Quantum ® system to process one complete apheresis product to yield a large number of mature and functional GMP-compliant monocyte-derived DCs for the use in cancer immunotherapy without any need for fibronectin coating or trypsin digestions.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research